JPWO2023132547A5 - - Google Patents

Info

Publication number
JPWO2023132547A5
JPWO2023132547A5 JP2024538390A JP2024538390A JPWO2023132547A5 JP WO2023132547 A5 JPWO2023132547 A5 JP WO2023132547A5 JP 2024538390 A JP2024538390 A JP 2024538390A JP 2024538390 A JP2024538390 A JP 2024538390A JP WO2023132547 A5 JPWO2023132547 A5 JP WO2023132547A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
chain variable
variable region
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501913A (ja
JP2025501913A5 (https=
Publication date
Priority claimed from KR1020220001647A external-priority patent/KR20230105972A/ko
Application filed filed Critical
Publication of JP2025501913A publication Critical patent/JP2025501913A/ja
Publication of JPWO2023132547A5 publication Critical patent/JPWO2023132547A5/ja
Publication of JP2025501913A5 publication Critical patent/JP2025501913A5/ja
Pending legal-status Critical Current

Links

JP2024538390A 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 Pending JP2025501913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2022-0001647 2022-01-05
KR1020220001647A KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
PCT/KR2022/021371 WO2023132547A1 (ko) 2022-01-05 2022-12-27 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도

Publications (3)

Publication Number Publication Date
JP2025501913A JP2025501913A (ja) 2025-01-24
JPWO2023132547A5 true JPWO2023132547A5 (https=) 2025-12-02
JP2025501913A5 JP2025501913A5 (https=) 2025-12-02

Family

ID=87073766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538390A Pending JP2025501913A (ja) 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用

Country Status (7)

Country Link
US (1) US20250074974A1 (https=)
EP (1) EP4461745A4 (https=)
JP (1) JP2025501913A (https=)
KR (1) KR20230105972A (https=)
CN (1) CN118510799A (https=)
AU (1) AU2022430428A1 (https=)
WO (1) WO2023132547A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189030A1 (en) * 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4897690B2 (ja) 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
PL3167888T3 (pl) * 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
BRPI0812767A2 (pt) * 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CA3056248A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
WO2019112958A1 (en) 2017-12-05 2019-06-13 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION

Similar Documents

Publication Publication Date Title
US12398204B2 (en) Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist
US11136389B2 (en) Humanized monoclonal antibodies that target VE-PTP (HPTP-β)
JP2020114218A5 (https=)
BR112019022751A2 (pt) composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
JP2018131467A (ja) 眼疾患の治療
JP2023130473A (ja) 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
JP2011503094A5 (https=)
US12540187B2 (en) Method of treating vascular eye and retinal diseases by administration of anti-Neuropilin 1A antibodies
JP2025011251A (ja) 眼の疾患の処置のためのアゴニスト性ＴｒｋＢ結合分子
JPWO2023132547A5 (https=)
JPWO2021194913A5 (https=)
JP2025525442A (ja) Ａｎｇ２／ｖｅｇｆ抗体およびその使用
WO2024114641A1 (en) C5/vegf bispecific binding molecules
US20260055171A1 (en) Vegf antagonists and methods of use thereof
RU2022102753A (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
HK40126782A (zh) C5/vegf双特异性结合分子
RU2021125763A (ru) Биспецифическое антитело, специфически связывающееся с vegf и ang2
EA046884B1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение